Ascletis Pharma Inc. has been involved in legal proceedings with Viking Therapeutics, Inc. over the importation of its drug candidates, ASC41 and ASC43F. In October 2024, the United States International Trade Commission issued an initial determination finding a violation of Section 337, recommending a seven-year exclusion order for these drugs. ASC41 is developed for treating non-alcoholic steatohepatitis (NASH) and targets thyroid hormone receptor beta (THRβ), while ASC43F is a fixed-dose combination targeting both THRβ and farnesoid X receptor $(FXR)$ for NASH treatment. Despite the ruling, Ascletis believes the outcome will not have a material adverse effect on its business and is seeking legal advice for an appeal. The company is committed to protecting its trade secrets and will provide updates on any significant developments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.